Literature DB >> 18594766

Efficacy of suicide gene therapy in hypoxic rat 9L glioma cells.

S Kumar1, S L Brown, A Kolozsvary, S O Freytag, J H Kim.   

Abstract

Viral vector mediated suicide gene therapy (SGT) involving thymidine kinase (TK) or cytosine deaminase (CD) have considerable promise in the treatment of malignant brain tumors. An unresolved issue is to what extent tumor hypoxia influences the outcome of SGT since brain tumors characterized by regions of hypoxia have potentially reduced cellular metabolism and SGT's cytotoxicity is manifest through cellular metabolism. We studied in vitro and in vivo, the effect of hypoxia on the cytotoxicity of SGT in rat 9L glioma cells. Neither acute nor chronic hypoxia affected the cell killing of SGT by TK or CD. In vivo confirmation that SGT efficacy was not adversely affected by tumor hypoxia using the hypoxic cell marker pimonidazole was shown by the absence of a change in tumor hypoxia by SGT. These studies support the use of SGT utilizing either TK or CD gene strategies even when tumors are characterized by a hypoxic microenvironment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18594766      PMCID: PMC3136088          DOI: 10.1007/s11060-008-9635-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  25 in total

1.  The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy.

Authors:  L H GRAY; A D CONGER; M EBERT; S HORNSEY; O C SCOTT
Journal:  Br J Radiol       Date:  1953-12       Impact factor: 3.039

2.  Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer.

Authors:  Svend O Freytag; Hans Stricker; James Peabody; Jan Pegg; Dell Paielli; Benjamin Movsas; Kenneth N Barton; Stephen L Brown; Mei Lu; Jae Ho Kim
Journal:  Mol Ther       Date:  2007-01-16       Impact factor: 11.454

3.  Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells.

Authors:  N Koshikawa; K Takenaga; M Tagawa; S Sakiyama
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

Review 4.  Barriers to drug delivery in solid tumors.

Authors:  R K Jain
Journal:  Sci Am       Date:  1994-07       Impact factor: 2.142

5.  Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix.

Authors:  B Jankovic; C Aquino-Parsons; J A Raleigh; E J Stanbridge; R E Durand; J P Banath; S H MacPhail; P L Olive
Journal:  Cytometry B Clin Cytom       Date:  2006-03       Impact factor: 3.058

Review 6.  How to overcome (and exploit) tumor hypoxia for targeted gene therapy.

Authors:  Olga Greco; Brian Marples; Michael C Joiner; Simon D Scott
Journal:  J Cell Physiol       Date:  2003-12       Impact factor: 6.384

Review 7.  Tumor microenvironment and the response to anticancer therapy.

Authors:  J Martin Brown
Journal:  Cancer Biol Ther       Date:  2002 Sep-Oct       Impact factor: 4.742

8.  Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors.

Authors:  J A Raleigh; S C Chou; G E Arteel; M R Horsman
Journal:  Radiat Res       Date:  1999-05       Impact factor: 2.841

9.  X irradiation combined with TNF alpha-related apoptosis-inducing ligand (TRAIL) reduces hypoxic regions of human gastric adenocarcinoma xenografts in SCID mice.

Authors:  Momoko Takahashi; Hironobu Yasui; Aki Ogura; Taketoshi Asanuma; Nobuo Kubota; Michihiko Tsujitani; Mikinori Kuwabara; Osamu Inanami
Journal:  J Radiat Res       Date:  2008-01-26       Impact factor: 2.724

10.  Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma.

Authors:  G Sersa; T Jarm; T Kotnik; A Coer; M Podkrajsek; M Sentjurc; D Miklavcic; M Kadivec; S Kranjc; A Secerov; M Cemazar
Journal:  Br J Cancer       Date:  2008-01-08       Impact factor: 7.640

View more
  2 in total

Review 1.  Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas.

Authors:  Rolf F Barth; Balveen Kaur
Journal:  J Neurooncol       Date:  2009-04-21       Impact factor: 4.130

Review 2.  Rat and Mouse Brain Tumor Models for Experimental Neuro-Oncology Research.

Authors:  Upasana Sahu; Rolf F Barth; Yoshihiro Otani; Ryan McCormack; Balveen Kaur
Journal:  J Neuropathol Exp Neurol       Date:  2022-04-27       Impact factor: 3.148

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.